A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Nebraska
Pharmacyclics LLC.
University of Chicago
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
M.D. Anderson Cancer Center
Werewolf Therapeutics, Inc.
Thomas Jefferson University
Acerta Pharma BV
Massachusetts General Hospital
Thomas Jefferson University
Bristol-Myers Squibb
Bayer
National Institutes of Health Clinical Center (CC)
Takeda
Universität des Saarlandes
Incyte Corporation
Stanford University
Celgene
University of Miami
Pharmacyclics LLC.
Celgene
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
PrECOG, LLC.
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Celgene
SCRI Development Innovations, LLC
Thomas Jefferson University
Thomas Jefferson University
Washington University School of Medicine
Incyte Corporation
Incyte Corporation
GlaxoSmithKline
Fred Hutchinson Cancer Center
City of Hope Medical Center
Juno Therapeutics, a Subsidiary of Celgene
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Denovo Biopharma LLC
University of Washington